Venova Medical has developed the VelocityTM pAVF System, a next generation percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation, maintain functionality and improve vascular access outcomes while reducing costs. Venova Medical has completed enrollment in a prospective, single center VENOS-1 clinical trial (NCT05757726) to evaluate the safety and feasibility of Velocity pAVF System in patients on hemodialysis who are candidates for AVF. The Results from the VENOS-1 study will be presented at the Controversies in Dialysis Access Conference (CiDA) on October 5, 2024.
Contact us to arrange a meeting with a member of our team to learn more about the Velocity™ System and the company’s efforts.
Meeting website: https://www.cxsymposium.com/